Harpoon Therapeutics Inc

NASDAQ:HARP  
15.05
-0.33 (-2.15%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)478.00M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$6.93 Million
Adjusted EPS-$0.43
See more estimates
10-Day MA$15.81
50-Day MA$19.55
200-Day MA$18.07
See more pivots

Harpoon Therapeutics Inc Stock, NASDAQ:HARP

131 Oyster Point Boulevard, Suite 300, South San Francisco, California 94080
United States of America
Phone: +1.650.443.7400
Number of Employees: 78

Description

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the bodyâ??s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.